Michael Barbella, Managing Editor06.25.22
Healthcare technology was the news of favor this week on the MPO website.
From artificial intelligence and virtual reality to lab-on-a-chip advancements, the ways in which the industry is melding technology with medicine drove most traffic.
Capturing the top spot, however, was an exclusive story about leveraging customer partnerships to accelerate growth, revenue, and product adoption. The tale by David Schnur Associates (DSA) President/CEO Barry Schnur details the process and decisions involved in representing Israeli contract manufacturer Medibrane outside of its home country, particularly in the United States. It was not an easy decision, but Schnur said his firm partnered with Medibrane because its initial focus was on structural heart applications and would complement DSA's offerings like laser cutting, nitinol, and delivery systems. "DSA's primary customers—R&D engineers—were exactly the customers Medibrane wanted to reach," Schnur writes.
Schnur's narrative about his company's partnership with Medibrane beat out news about AI innovations drivin medtech M&A and a new study that validates VR training efficacy. Other technology-related news of interest this week was the next-generation diagnostic tests under development at the University of Kansas, and NHS England selecting a Terumo solution to treat sickle cell disease. NHS England chose the automated red blood cell exchange (RBCX) procedure performed on Terumo Blood and Cell Technologies’ Spectra Optia(R) Apheresis System to treat sickle cell disease, one of the most common genetic conditions affecting people in England. There are currently more than 12,000 patients receiving treatment in 68 different NHS hospitals; 40% of those patients are under 20 years old.
The University of Kansas, meanwhile, is working on a better method to detect cancer, stroke, and COVID-19 through technology developed by its Center of BioModular Multi-Scale Systems for Precision Medicine (CBM2). Awarded $6.6 million in continued funding over the next five years from the National Institutes of Health's National Institute of Biomedical Imaging and Bioengineering (NIBIB), CBM2 takes small plastic chips made of the same material as a compact disc and transforms them into marvels of engineering and chemistry that quickly can detect hard-to-diagnose human diseases using saliva, urine or blood from a patient. The liquid biopsies can detect circulating tumor cells, cell-free DNA, viruses and vesicles that are released by biological cells associated with a particular disease.
From artificial intelligence and virtual reality to lab-on-a-chip advancements, the ways in which the industry is melding technology with medicine drove most traffic.
Capturing the top spot, however, was an exclusive story about leveraging customer partnerships to accelerate growth, revenue, and product adoption. The tale by David Schnur Associates (DSA) President/CEO Barry Schnur details the process and decisions involved in representing Israeli contract manufacturer Medibrane outside of its home country, particularly in the United States. It was not an easy decision, but Schnur said his firm partnered with Medibrane because its initial focus was on structural heart applications and would complement DSA's offerings like laser cutting, nitinol, and delivery systems. "DSA's primary customers—R&D engineers—were exactly the customers Medibrane wanted to reach," Schnur writes.
Schnur's narrative about his company's partnership with Medibrane beat out news about AI innovations drivin medtech M&A and a new study that validates VR training efficacy. Other technology-related news of interest this week was the next-generation diagnostic tests under development at the University of Kansas, and NHS England selecting a Terumo solution to treat sickle cell disease. NHS England chose the automated red blood cell exchange (RBCX) procedure performed on Terumo Blood and Cell Technologies’ Spectra Optia(R) Apheresis System to treat sickle cell disease, one of the most common genetic conditions affecting people in England. There are currently more than 12,000 patients receiving treatment in 68 different NHS hospitals; 40% of those patients are under 20 years old.
The University of Kansas, meanwhile, is working on a better method to detect cancer, stroke, and COVID-19 through technology developed by its Center of BioModular Multi-Scale Systems for Precision Medicine (CBM2). Awarded $6.6 million in continued funding over the next five years from the National Institutes of Health's National Institute of Biomedical Imaging and Bioengineering (NIBIB), CBM2 takes small plastic chips made of the same material as a compact disc and transforms them into marvels of engineering and chemistry that quickly can detect hard-to-diagnose human diseases using saliva, urine or blood from a patient. The liquid biopsies can detect circulating tumor cells, cell-free DNA, viruses and vesicles that are released by biological cells associated with a particular disease.